Related Experiment Video
Updated: Nov 16, 2025

A Fibrin-Enriched and tPA-Sensitive Photothrombotic Stroke Model
Published on: June 4, 2021
Covid-19 and Thrombotic Thrombocytopenic Purpura: A Case Report
Maryam Darnahal1, Hamed Azhdari Tehrani1, Mohammad Vaezi2
1Department of Hematology and Medical Oncology, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Insights
Thrombotic thrombocytopenic purpura (TTP) is a rare condition linked to COVID-19. This case report details the fourth patient identified with TTP associated with the novel coronavirus, highlighting a potential link.
Area of Science:
- Hematology
- Infectious Diseases
- Critical Care Medicine
Background:
- Thrombotic microangiopathies (TMAs) arise from endothelial injury, activating coagulation and leading to organ dysfunction.
- Platelet consumption and red blood cell injury are hallmarks of TMAs.
Observation:
- This case report describes the fourth patient diagnosed with thrombotic thrombocytopenic purpura (TTP).
- The patient presented with TTP in association with COVID-19.
Findings:
- COVID-19 can precipitate TTP, a serious thrombotic microangiopathy.
- The association between SARS-CoV-2 infection and TTP is increasingly recognized.
Implications:
- Understanding this association is crucial for timely diagnosis and management of TTP in COVID-19 patients.
- Further research is warranted to elucidate the pathogenic mechanisms linking COVID-19 and TTP.
- Early recognition and treatment may improve outcomes for patients with concurrent COVID-19 and TTP.
Abstract:
Endothelial injury by toxins, drugs, immune complexes leads to activation of coagulation cascade and thrombosis, which result in platelet consumption and red blood cell injury. These thrombotic microangiopathies can potentially injure numerous organs and result in organ dysfunction. In this case, we present the fourth reported patient with thrombotic thrombocytopenic purpura associated with COVID-19.
More Related Videos
11:18Real-time Imaging of Heterotypic Platelet-neutrophil Interactions on the Activated Endothelium During Vascular Inflammation and Thrombus Formation in Live Mice
Published on: April 2, 2013
05:49Procoagulant Platelet Characterization by Measuring Phosphatidylserine Exposure and Microvesicle Release from Human Purified Platelets
Published on: November 29, 2024
Related Concept Videos
Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies
Venous Thrombosis III: Interprofessional Care
Venous Thrombosis I: Introduction
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
Disorders of Hemostasis
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Anticoagulant Drugs: Low-Molecular-Weight Heparins